Cipher Pharmaceuticals Inc shares have seen a slight decline in the past week, reflecting broader trends in the health care sector.
Cipher Pharmaceuticals Inc (CPH.TO) has experienced a modest downturn in its stock price, closing at C$16.43, down 1.16% for the day and 0.91% over the past week. Despite recent financial reports showcasing impressive year-over-year growth, the stock has not been able to maintain upward momentum in the short term.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Cipher Pharmaceuticals Inc
CPH.TO
CPH.TO
Cipher Pharmaceuticals Inc
WealthAwesomeMarket cap
$416.93M
P/E
9.7x
52W high
$20.56
52W low
$11.98
1W change
+0.06%
Beta
0.48
Analyst Price Targets
Based on analyst covering CPH
Wall Street analysts forecast CPH stock price to rise 25.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$20.64
+25.6% Upside
Current Price
C$16.43
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CPH's historical volatility
30-Day Vol
19.5%
Annualized
90-Day Vol
33.3%
Annualized
Trend (90d)
-31.5%
Annualized drift
90d Mean
C$14.68
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$15.83 | C$14.80 – C$16.92 |
| 60 trading days | C$15.24 | C$13.86 – C$16.76 |
| 90 trading days | C$14.68 | C$13.07 – C$16.49 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: While Cipher has demonstrated strong financial performance, the recent price action may concern investors looking for stability. The company’s fundamentals remain solid, but the stock's recent performance suggests caution is warranted.
Cipher Pharmaceuticals Reports Record Revenue Growth
Cipher Pharmaceuticals reported a remarkable 51% increase in total revenue for 2025, reaching $50.5 million, showcasing its ability to grow amidst market challenges.
Bull case
Cipher's strong profit margins and return on equity show it is well-managed and has potential for continued growth. Analysts are optimistic, with an average target price indicating significant upside from current levels.
Bear case
The recent drop in stock price, along with lower trading volumes compared to the 20-day average, could signal a lack of investor confidence. The stock's beta of 0.48 suggests it may be less volatile than the market, which could limit growth potential in a bullish market environment.
Recent Price Action
Cipher Pharmaceuticals Inc shares closed at C$16.43, marking a 1.16% decrease for the day and a 0.91% decline over the past week. Year-to-date, the stock has gained 9.06%, reflecting a more positive trend earlier in the year.
Company News and Web Headlines
There were no major company announcements this week, but recent headlines highlight Cipher's strong financial performance. The company reported a record-high revenue of $50.5 million for 2025, a 51% increase over the previous year. This growth is indicative of Cipher's robust business model and market position, particularly in its specialty pharmaceutical offerings.
Technical Picture
The technical indicators for Cipher Pharmaceuticals show a mixed picture. The stock is currently trading slightly below its 50-day moving average of C$16.64, indicating some short-term weakness. However, it is above its 200-day moving average of C$15.86, suggesting a longer-term uptrend. The 52-week range of C$11.98 to C$20.56 indicates that the stock is currently trading at approximately 52% of its range, which may suggest room for growth if positive momentum can be regained. The current volume of 9,821 shares is lower than the 20-day average of 12,900 shares, indicating reduced trading activity.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
